Deprecated: Function get_magic_quotes_gpc() is deprecated in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 152

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 469

Notice: Undefined property: stdClass::$live in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 474

Notice: Undefined variable: type in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 560

Notice: Undefined variable: sortString in /home/uchis2/domains/uchisearch.com/public_html/category.php on line 563
AGENT METHODS

AGENT METHODS

Brand Owner Address Description
AGENTMETHODS AgentMethods 11 Bowen Road Asheville NC 28803 AGENT METHODS;Providing advertising and marketing services for the insurance industry; development of advertising campaigns for online medium; advertising management consultancy for advertising campaigns;Providing online software and marketing applications for the insurance industry, namely, providing online non-downloadable software enabling personalized web site design, and providing hosting and maintenance services with respect thereto; providing online non-downloadable software for use in lead generation and lead management for the insurance industry;
 

Where the owner name is not linked, that owner no longer owns the brand

   
Technical Examples
  1. A specific binding agent is provided, wherein the specific binding agent specifically binds Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin-6 (vIL-6), and the specific binding agent neutralizes an activity of vIL-6. In one embodiment, the specific binding agent is an antibody. Methods are provided for using a specific binding agent that binds vIL-6, and neutralizes a biological activity of vIL-6. Methods of treatment for a KSHV-associated disorder are also provided. Methods for diagnosing a KSHV-associated disorder are provided, as are kits that include a specific binding agent of the invention. A method is also provided for testing an agent for effectiveness in treating a KSHV-associated disorder. The method includes incubating the agent with a cell free system comprising a vIL-6 receptor component and vIL-6, and comparing the binding of vIL-6 and the receptor component in the presence of the agent to binding of vIL-6 to the receptor component in the absence of the agent. A decrease in the binding of vIL-6 to the receptor component in the presence of the agent indicates that the agent is effective for treating the KSHV-associated disorder.